【when is santa muerte birthday】Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.38. This when is santa muerte birthdaycompares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -42.11%. A quarter ago, it was expected that this drugmaker would post a loss of $0.44 per share when it actually produced a loss of $0.27, delivering a surprise of 38.64%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $120.58 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 1.52%. This compares to year-ago revenues of $94.59 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Acadia?
While Acadia has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.45 on $123.49 million in revenues for the coming quarter and -$1.65 on $442.47 million in revenues for the current fiscal year.
Story continues
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
View comments
相关文章
Read This Before Selling Altura Mining Limited (ASX:AJM) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to imp2024-09-29- SUFFERN, NY--(Marketwired - May 4, 2014) - CDx Diagnostics today announced results from a study show2024-09-29
Could The IXUP Limited (ASX:IXU) Ownership Structure Tell Us Something Useful?
Every investor in IXUP Limited (ASX:IXU) should be aware of the most powerful shareholder groups. In2024-09-29Need To Know: DNB Financial Corporation (NASDAQ:DNBF) Insiders Have Been Selling Shares
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to imp2024-09-29U.S. CDC reports 1,827,425 coronavirus cases
June 3 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday reported 12024-09-29Simulmedia Is First to Launch Guaranteed TV Ad Campaigns Using TRA's Purchase Data
NEW YORK, NY--(Marketwired - Oct 1, 2013) - Simulmedia, a targeted television advertising company, a2024-09-29
最新评论